Please login to the form below
antimicrobial
This page shows the latest antimicrobial news and features for those working in and with pharma, biotech and healthcare.
EMA cuts back as Brexit staff losses top expectations
That means less urgent matters such as harmonisation will be will be dealt with only on a reactive basis, and other topics such as antimicrobial resistance will be considered on a
Latest news
-
Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator
Europe launches antimicrobial research ‘Accelerator’. A new Antimicrobial Resistance (AMR) Accelerator Programme has been unveiled by the EU and pharma-funded Innovative Medicines Initiative (IMI). ... Pierre Meulien, IMI Executive Director commented:
-
Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator
Europe launches antimicrobial research ‘Accelerator’. A new Antimicrobial Resistance (AMR) Accelerator Programme has been unveiled by the EU and pharma-funded Innovative Medicines Initiative (IMI). ... Pierre Meulien, IMI Executive Director commented:
-
Daily Brief: Novartis exits anti-infectives drive, Hancock takes over from Hunt and Trump attacks 'soft Brexit' plan
The latest from pharma, biotech and healthcare. Novartis joins big pharma’s antimicrobial research exodus.
-
Evotec says Sanofi deal makes it anti-infectives powerhouse
regulatory approvals of course – and that will give it “the highest qualified translational footprint in infectious disease research globally.”It will focus initially on antimicrobial resistant (AMR) infections, tuberculosis, and malaria,
-
Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more
AMR. UK pledges £30m to fight antimicrobial resistance. The UK has taken a lead in co-ordinating international action to counter antimicrobial resistance in the last few years, and has just
More from news
Approximately 39 fully matching, plus 67 partially matching documents found.
Latest Intelligence
-
Rules of engagement
Fewer than half of the nearly 10, 000 respondents had heard of the term ‘antimicrobial resistance’.
-
No incentive for a cure
The stakes are too high for this not to happen. The risk we face from antimicrobial resistance and the current lack of new antibiotics tells us all we need to know
-
The threat of antimicrobial resistance
The threat of antimicrobial resistance. Why this issue is such a fundamental challenge. ... A look at some of the headline statistics on the antimicrobial resistance (AMR) issue is particularly sobering.
-
Significant figures
us.”. An inhaled formulation of last-resort antibiotic Amikacin, ALIS taps into a need for new antibiotics as well as industry heads towards more joined-up thinking to tackle antimicrobial resistance.
-
Deal Watch March 2017
60. Cipla Agrimed. Ascendis Health. Acquisition. Veterinary antimicrobials and endectocides. 29.
More from intelligence
Approximately 6 fully matching, plus 7 partially matching documents found.
Latest appointments
-
IFPMA names new communications director
and to enable government to meet ambitious goals such as universal health coverage, global health security and continued innovation in areas of high unmet health needs such as antimicrobial resistance.
-
Destiny Pharma appoints new CEO
Destiny Pharma has appointed Neil Clark as CEO as the Brighton, UK-based firm plans a phase IIb trial for its lead antimicrobial candidate.
-
New health ministers and re-appointments after reshuffle
Ellison, who reprises her role as the secretary for public health that she has held since 2013, also has a wide remit that includes pharma as will have responsibility for: antimicrobial
-
Xellia forms scientific advisory board
drugs to help tackle the global crisis of antimicrobial resistance.”. ... Antimicrobial resistance is a huge area of unmet medical need and one of the greatest threats to human health.
-
Cubist picks Robert Perez as its new CEO
area as the world recognises the growing threat of antimicrobial resistance.
More from appointments
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Animal Healthcare Market to Soar at 4% CAGR to 2024
Stringent regulations in many countries pertaining to use of antibiotics and antimicrobials in animal feed, high cost associated with animal testing and low out-of-pocket pet healthcare expenditure in developing
-
Interesting Research Report on the Future of Staphylococcus Aureus Testing Market
According to the SENTRY Antimicrobial Surveillance Program the prevalence of Staphylococcus Aureus related disease in North America (26.0%), Latin America ( 21.6%) and in Europe ( 19.5%).
-
Animal Healthcare Market is poised to cross USD 36 billion by 2024
On the other side, market expansion restraining factors such as anitibiotics and antimicrobials prohibition in animal food in number of regions across the globe will be animal healthcare industry growth impeding
-
Antibiotic Resistance: Alarm bells ring louder than ever
where antibiotics and the threat of antimicrobial resistance (AMR) became a hot topic in the mainstream media. ... Another angle is the development of small molecules that can be administered in conjunction with antimicrobials to prevent resistance
-
Cello Health
Though international focus is turning to antimicrobial resistance and incentives are being provided for research into new drugs, there are many hurdles to be jumped before a blockbuster can be discovered
More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.
Featured jobs
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
- Account Manager- Healthcare Advertising
-
Negotiable
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Senior Account Manager
-
Competitive Salary Offered
-
Medical Writer
-
Bonus Scheme, PTO &Private Healthcare
-
Account Director
-
Competitive Salary Offered
-
Experienced Medical Writers
-
Competitive Salary and Benefits
- Business Development Director – Health Education
-
excellent commission
-
Systematic Reviewer - Oxford
-
Negotiable
- Principal Health Economist - North-West
-
Negotiable
-
Account Manager
-
Negotiable
-
Associate Director
-
£75, 000-90, 000
-
Medical (Scientific) Director
-
£120, 000 benefits
Subscribe to our email news alerts
- Industry frustrated by late warning on 'no deal' Brexit disruption
- UK’s genomics leadership attracts IQVIA investment, regardless of Brexit
- Lucid Group celebrate another magical year at their Winter Meeting
- Biogen picks up another drug from wide-ranging Ionis alliance
- As France protests, Sanofi takes axe to 670 jobs
- Leicester NHS Trust’s staff intranet is integral to HCPs’ working day
Latest intelligence
- Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
- What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
- What everyone forgets about good organisational change in pharma
- Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
- Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
- Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...
Quick links
Infographics
